Phase 3 Readout

TBPH: Phase 3 Topline: A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for th

Name: Phase 3 Topline: A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for th
Start: 2028-01-01
End: 2028-01-01

January 1, 2028 · ampreloxetine. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 1, 2028
Company: Theravance Biopharma, Inc. (TBPH)
Drug: ampreloxetine

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for th

January 1, 2028

TBPH overview →

Company: Theravance Biopharma, Inc. (TBPH)
Drug: ampreloxetine
Indication: Symptomatic Neurogenic Orthostatic Hypotension; MSA - Multiple System Atrophy